In March 2008, the European Commission granted marketing authorization for dabigatran etexilate (Pradaxa; Boehringer Ingelheim), a direct thrombin inhibitor, for the prevention of venous ...
The mean follow-up duration was 20 months. In the NOAC group, apixaban (Eliquis; Bristol Myers Squibb/Pfizer) was used in four trials, rivaroxaban (Xarelto; Janssen/Bayer) in two trials, dabigatran ...
Purpose. The pharmacology, pharmacokinetics, clinical efficacy, tolerability, dosage and administration, and place in therapy of dabigatran etexilate are reviewed. Summary. Dabigatran is a ...
Among those assigned to a DOAC, 53.8% used apixaban (Eliquis, Bristol Myers Squibb/Pfizer), 20.9% used dabigatran (Pradaxa, Boehringer Ingelheim), 18.4% used edoxaban (Savaysa, Daiichi Sankyo ...
where Boehringer Ingelheim also has a blockbuster with Pradaxa (dabigatran). In the US, Janssen booked sales of $549 million in the last quarter, down almost 19% compared with the same period last ...
Am J Health Syst Pharm. 2011;68(16):1506-1519. The higher rate of myocardial infarction seen in the dabigatran groups is concerning. It is unclear what caused the increased rate of myocardial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback